Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof

A technology of inactivated vaccines and multivalent vaccines, which can be used in medical preparations containing active ingredients, biochemical equipment and methods, microorganisms, etc., and can solve the problem of not finding prevention and treatment drugs.

Inactive Publication Date: 2010-06-16
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a normal epidemic season, about 10% of the population, or more than 500 million people, suffer from influenza. At present, no ideal prevention and treatment drugs have been found. Influenza vaccination is still an effective measure to prevent influenza today.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof
  • Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof
  • Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Example 1: Chicken embryo culture to obtain influenza pentavalent vaccine antigen

[0131] Seasonal influenza (H1N1, H3N2, type B), highly pathogenic H5N1 human avian influenza, and influenza A H1N1 influenza virus vaccine strains are provided by the US CDC and the UK NIBSC.

[0132] Inoculate seasonal influenza (H1N1, H3N2, type B), highly pathogenic H5N1 human avian influenza and influenza A H1N1 influenza virus vaccine strains into the allantoic cavity of 9-11-day-old SPF chicken embryos, and culture them at 33-35°C for 48-72h The chicken embryos were frozen overnight in a refrigerator at 4°C, and the allantoic fluid of the chicken embryos was harvested to obtain a large amount of virus. After the viruses were harvested, they were filtered through a filter with a pore size of 0.45 μm to obtain the influenza pentavalent vaccine antigen.

Embodiment 2

[0133] Example 2: Chicken embryo culture to obtain influenza multivalent vaccine antigen

[0134] Seasonal influenza (H1N1, H3N2, type B), highly pathogenic H5N1 human avian influenza, influenza A H1N1 and other subtype influenza virus strains were provided by CDC in the United States and NIBSC in the United Kingdom.

[0135] Inoculate the allantoic cavity of 9-11-day-old SPF chicken embryos with seasonal influenza (H1N1, H3N2, B-type), highly pathogenic H5N1 human avian influenza, A-H1N1 influenza and other subtype influenza virus strains, at 33-35°C Cultivate for 48-72 hours, freeze the chicken embryos overnight in a 4°C refrigerator, harvest the allantoic fluid of the chicken embryos to obtain a large amount of virus, and after the virus is harvested, pass it through a filter for clarification and filtration to obtain influenza or multivalent vaccine antigens.

Embodiment 3

[0136] Example 3: Mammalian cells (such as Vero cells, MDCK cells, Per.C6 cells, 2BS cells, etc.) were cultured to obtain influenza pentavalent vaccine antigens

[0137] Seasonal influenza (H1N1, H3N2, type B), highly pathogenic H5N1 human avian influenza, and influenza A H1N1 influenza virus vaccine strains are provided by the US CDC and the UK NIBSC.

[0138] Cultured cells: Mammalian cell lines used for vaccine production (such as Vero cells, MDCK cells, Per.C6 cells, 2BS cells, etc.) were planted in 15L spinner bottles at a ratio of 1:6, cultured for 2-3 days and then inoculated with influenza virus vaccines Strains, including seasonal influenza (H1N1, H3N2, type B), highly pathogenic H5N1 human avian influenza and influenza A (H1N1) influenza virus vaccine strains; wherein the cells are recovered from the working generation cell bank and obtained through passage amplification;

[0139] Inoculation of virus: at cell density up to 3 x 10 6 Inoculate the virus with a multip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and preparation method thereof. The vaccine is inactivated vaccine antigen of totivirus, lytic virus, viron or virus-like particles, flue multivalent vaccine antigen is flue pentavalent, namely H1N1, H3N2, B, H5N1 and A (H1N1) or multivalent vaccine antigen combined on the basis at will, or flue multivalent vaccine antigen obtained by containing all the combination of the HA selecting from H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 and H16 and the NA selecting from N1, N2, N3, N4, N5, N6, N7, N8 and N9 subtypes on the basis. The content of flu multivalent inactivated vaccine antigen HA in the vaccine of the invention is 1.0-15.0 Mug/0.2ml/per person, and the vaccine of the invention can effectively prevent routine human flue, high pathogenicity H5N1 avian-human flu, influenza A (H1N1) and infection of other subtype influenza viruses.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals and relates to a vaccine and a preparation method thereof, in particular to a pentavalent or multivalent inactivated vaccine for nasal immunization with influenza and a preparation method thereof. Background technique [0002] Influenza is a disease mainly caused by influenza virus that damages the respiratory system. It is widely prevalent in the world and is one of the important infectious diseases that seriously endanger human health. Influenza virus infection is initiated by attachment of the virion surface HA protein to sialic acid-containing cell receptors (glycoproteins and glycolipids). NA proteins mediate the processing of sialic acid receptors, and virus entry into cells depends on HA-dependent receptor-mediated endocytosis. In the acidic realm of internalized influenza virion-containing endosomes, the HA protein undergoes a conformational change that leads to fusion of the viral and h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/295A61K39/145A61K39/39A61P31/16C12N7/00
Inventor 杨鹏辉王希良罗德炎段跃强邢丽刘坤赵忠鹏王铖
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap